Login | Contact Us | Join | Site Map | TS Home
Annual Meeting 2013
Meeting Information Program Registration Hotel Abstracts Students & Postdoc Sponsors
Meeting Program

(information subject to change)

Overview | Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday

Monday, June 24, 2013

 

 

7:00 AM–8:00 AM DINE WITH A TERATOLOGY AMBASSADOR
  (Advance Signup Required)
   
7:00 AM–8:00 AM BDRB EDITORIAL BOARD MEETING—Executive Boardroom
   
7:00 AM–8:00 AM FINANCE COMMITTEE MEETING—Santa Rita
   
7:00 AM–6:00 PM REGISTRATION—Grand Ballroom Foyer
   
7:00 AM–6:00 PM SPEAKER READY ROOM OPEN
   
8:00 AM–8:30 AM THALIDOMIDE ARCHIVE—Salon B
   
8:30 AM–9:00 AM ROBERT L. BRENT LECTURE: TERATOGEN UPDATE—Salon B
  Noninvasive Prenatal Diagnosis (NIPD) Using Cell-Free Fetal DNA (L7)

 

Chairperson: Edward W. Carney, The Dow Chemical Company
Lecturer: Joe Leigh Simpson, March of Dimes Foundation
   
9:00 AM–12:00 NOON

PLATFORM SESSION 2—Catalina Ballroom

  Molecular and Cellular Mechanisms of Abnormal Development
  Chairpersons: Carolyn Kapron, Trent University and Louise M. Winn, Queen's University
   
9:00 AM–9:15 AM   Introduction
     
9:15 AM–9:30 AM 9 Evaluation of Signaling Pathway Perturbation Using a Kinase Inhibitor Chemical Library in Mouse Embryonic Stem Cells ACDC Assay
    Hunter S, Rosen M, Jeffay S, Hoopes M, Nichols H, Chandler K. ISTD, NHEERL, US EPA, Research Triangle Park, NC, United States.
     
9:30 AM–9:45 AM 10 Inhibition of Glutathione Biosynthesis Alters Compartmental Redox Status and the Thiol Proteome in Organogenesis-Stage Rat Conceptuses
   

Hanasen JM1, Harris C2, Gomez RR2, Schuster DZ2, Sant KE2, Pohl J3, Reed M3. 1Emory University, Atlanta, GA, United States, 2University of Michigan, Ann Arbor, MI, United States, 3Center for Disease Control and Prevention, Atlanta, GA, United States.

     
9:45 AM–10:00 AM 11 Valproic Acid Causes p53 Hyperacetylation and Inhibits Activation of the Autophagy Inhibitor mTOR in Murine Limb Buds
    Paradis FH, Hales BF. McGill University, Montreal, QC, Canada.
     
10:00 AM–10:15 AM   Break
     
10:15 AM–10:30 AM 12 A Proposed Mechanism for Thalidomide-Induced Limb Malformations
    Scott WJ. Children's Hospital Research Foundation, Cincinnati, OH, United States.
     
10:30 AM–10:45 AM 13 A Comparative Assessment of Maternal Reproductive Parameters, Fetal Viability, and Hypertension with Surgical and Nonsurgical Models of Preeclampsia in the Sprague Dawley Rat
   

Toot JD1, Coder PS1, Gleason TR1, Edwards TR1, Moehle RM1, Loris SM1, Reho JJ2. 1WIL Research Laboratories, Ashland, OH, United States, 2University of Maryland, Baltimore, Department of Medicine, Division of Cardiology, Baltimore, MD, United States.

     
10:45 AM–11:00 AM 14 In Utero Caffeine Exposure Alters DNA Methylation Patterns and Gene Expression in Hearts
   

Fang X, Rivkees SA, Wendler CC. University of Florida, Gainesville, FL, United States.

     
11:00 AM–11:15 AM 15 The Splotch Allele Increases Sensitivity to NTDs Produced by High Doses of Arsenite and Cadmium Individually but Not to NTDs Caused by Lower Doses of Both in Combination: Implications for Mechanisms of Action
   

Machado AF, Huynh FK, Chung YE. Environmental and Occupational Health, California State University, Northridge, Northridge, CA, United States.

     
11:15 AM–11:30 AM 16 The Familial Nature of Renal Agenesis
    Clark JC1, Manak J1, Darbro B1, Kannan P2, Holmes LB2, Brophy PD1. 1University of Iowa, Iowa City, IA, United States, 2MassGeneral Hospital for Children, Boston, MA, United States.
     
11:30 AM–11:45 AM 17 Decreased Reproduction in Mice from Tap Water Exposure in a Facility Using QAC Disinfectants
   

Hrubec TC1,2, Sugrue JE2. 1Via College of Osteopathic Medicine, Blacksburg, VA, United States, 2VA-MD Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, United States.

     
11:45 AM–12:00 NOON   Discussion
   

9:00 AM–12:30 PM

TS/OTIS JOINT ILSI-HESI SYMPOSIUM—Salon B

 

Communication of Risk for Medication Use in Pregnancy and Lactation

 

Chairpersons: Christina D. Chambers, University of California, San Diego, Jane Stewart, AstraZeneca Pharmaceuticals, and Melissa S. Tassinari, US Food and Drug Administration

   
9:00 AM–9:05 AM   Introduction
    Melissa S. Tassinari, US Food and Drug Administration
     
Anticipating a Pregnancy and Lactation Label without Letters
     
9:05 AM–9:20 AM S9 Navigating Pregnancy and Lactation Labeling without Letters:  A Review of the Proposed Changes to Product Labeling
    Melissa S. Tassinari, US Food and Drug Administration
     
9:20 AM–9:35 AM S10 The Animal Data: Making It Clear and Relevant
    Melissa S. Tassinari, US Food and Drug Administration
     
9:35 AM–9:50 AM S11 Anticipated Improvements to Human Data Content in the Proposed US FDA Pregnancy Label
    Cheryl S. Broussard, Centers for Disease Control and Prevention
     
9:50 AM–10:00 AM   Questions for Speakers
     
10:00 AM–10:15 AM   Break
     
Where Do the Data Come From?
     
10:15 AM–10:30 AM S12 Maximizing the Value of the Nonclinical Data for Evaluation of Risk in Pregnancy and Lactation
    Susan Bielmeier Laffan, GlaxoSmithKline
     
10:30 AM–10:45 AM S13 Data Collection Methods for Use of Medications in Pregnancy
    Melissa S. Tassinari, US Food and Drug Administration
     
10:45 AM–11:00 AM S14 Electronic Health Records and Beyond: Exploring Innovative New Data Sources
    Sara H. Riordan, Lifetech
     
11:00 AM–11:10 AM   Questions for Speakers
     
Communication of Reproductive Risk
     
11:10 AM–11:25 AM S15 Using Animal and Human Data to Communicate Risk: Perspectives of a Clinician
    Lisa L. Mathis, Amgen
     
11:25 AM–11:40 AM S16 Putting the Risk in Context: Communicating the Impact of the Underlying Disease Condition and Pharmacotherapy during Pregnancy
    Katherine L. Wisner, Northwestern University
     
11:40 AM–11:55 AM S17 How Is Risk Perceived amongst Patients?
    Sarah G. Obican, Columbia University
     
11:55 AM–12:05 PM   Questions for Speakers
     
12:05 PM–12:30 PM   Panel Discussion
     

 

 

12:30 PM–1:30 PM

LUNCH ON YOUR OWN

   
12:30 PM–1:30 PM

PAST PRESIDENTS’ AND HONOREES’ LUNCHEON—Santa Rita

  (By Invitation Only)
   

1:45 PM–3:30 PM

PLATFORM SESSION 3—Catalina Ballroom

  Hazard Assessment, Risk Characterization, and Risk Management of Pre- and Postnatal Impacts on Development
 

Chairpersons: Linda G. Roberts, Chevron Energy Technology Company and
Jason Stanko, National Institute of Environmental Health Sciences

1:45 PM–2:00 PM   Introduction
     
2:00 PM–2:15 PM 18 Time Course for Onset and Recovery of Effects of a Novel Male Reproductive Toxicant: Implications for Apical Preclinical Study Designs
    Stewart J. AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom.
     
2:15 PM–2:30 PM 20 Dose Response of Listeria monocytogenes Invasion and Fetal Mortality during Pregnancy
    Roulo RM, Fishburn JD, Smith MA. University of Georgia, Athens, GA, United States.
     
2:30 AM–2:45 PM 21 Effects of Developmental PCB Exposure on Energy Metabolism in Mice from Three Months to 12 Months of Age
    Curran CP, Brown A, Ashworth A, Branham J, Smith K, Earnheart A. Northern Kentucky University, Highland Heights, KY, United States.
     
2:45 PM–3:00 PM 22 MicroPET/CT Imaging of [18F]-FEPPA in the Nonhuman Primate: A Potential Biomarker of Pathogenic Processes Associated with Anesthetic-Induced Neurotoxicity
   

Slikker Jr. W1, Zhang X1, Paule MG1, Newport GD1, Liu F1, Callicott R1, Liu S1, Berridge M2,3, Apana SM2,3, Wang C1. 1National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, United States, 23D Imaging, LLC, Little Rock, AR, United States, 3University of Arkansas for Medical Sciences, Little Rock, AR, United States.

     
3:00 PM–3:15 PM 24 Preventing Birth Defects: It Is About Time!
    Brent RL, Oakley GP. Alfred I. duPont Hospital for Children, Wilmington, DE, United States.
     
3:15 PM–3:30 PM   Discussion

 

 

1:30 PM–6:00 PM

TS/NBTS JOINT SYMPOSIUM—Salon A

  Honoring the Legacy of Dr. Patricia M. Rodier

 

Chairpersons: Chris Stodgell, University of Rochester and Charles V. Vorhees, Cincinnati Children’s Research Foundation

   
1:30 PM–1:45 PM   Memories of Patricia M. Rodier
    Richard E. Butcher
     
1:45 PM–2:30 PM S18 Manganese Neurotoxicity: From Worms to Neonates
    Michael Aschner, Vanderbilt University
     
2:30 PM–3:15 PM S19 Cross-Species Comparisons of the Effects of Developmental Methylmercury Exposure: An Update of a Collaborative Project with Dr. Patty Rodier
    Thomas Burbacher, University of Washington
     
3:15 PM–4:00 PM S20 Teratology of Autism: From Animal Models to Endophenotypes
    Chris J. Stodgell, University of Rochester
     
4:00 PM–4:30 PM   Break
     
4:30 PM–5:15 PM S21 Thalidomide, Moebius Syndrome/Sequence and Misoprostol: Pieces to the Autism Puzzle
    Marilyn T. Miller, University of Illinois
     
5:15 PM–6:00 PM S22 Syndromes and the Study of Autism
    Tara L. Wenger, Children's Hospital of Philadelphia

 

 

1:30 PM–6:00 PM TS/OTIS JOINT PREGNANCY REGISTRY WORKSHOP—Salon B
  Pregnancy Registry Designs That Involve Multiple Drugs for Similar Indications: Advantages, Disadvantages, and Sustainable Funding Models
  Chairpersons: Vincent T. Armenti, NTPR, Gift of Life Institute and Lee S. Cohen, Massachusetts General Hospital
1:30 PM–1:40 PM   Introduction and Overview
    Lewis B. Holmes, MassGeneral Hospital for Children
     
1:40 PM–2:00 PM W1 Pregnancy Registry Designs for Multiple Drugs for Similar Medications: North American AED (Antiepileptic Drug) Pregnancy Registry
    Lewis B. Holmes, MassGeneral Hospital for Children
     
2:00 PM–2:20 PM W2 The National Pregnancy Registry for Atypical Antipsychotics: Effects of Fetal Exposure on Risk for Congenital Malformations and Maternal/Newborn Outcomes
    Lee S. Cohen, Massachusetts General Hospital
     
2:20 PM–2:40 PM W3 Celebrating 20 Years: The Antiretroviral Pregnancy Registry
    Susan Sinclair Roberts, University of North Carolina, Wilmington
     
2:40 PM– 3:00 PM W4 National Transplantation Pregnancy Registry
    Vincent T. Armenti, NTPR, Gift of Life Institute
     
3:00 PM–3:30 PM W5 Is a Multisite Model for Collaboration across Investigators Feasible for a Single Multidrug Registry?
    Gideon Koren, The Hospital For Sick Children
     
3:30 PM–4:00 PM W6 How Should Classes of Medications Be Prioritized for Multidrug Approaches and How Can Generics Be Incorporated into These Efforts?
    Melissa S. Tassinari, US Food and Drug Administration
     
4:00 PM–4:15 PM   Break
     
4:15 PM– 4:45 PM W7 Utility of Multidrug Disease-Based Pregnancy Registries to Inform Clinical Management Guidelines
    Cheryl S. Broussard, Centers for Disease Control and Prevention
     
4:45 PM– 5:00 PM   Discussion
     
5:00 PM–5:15 PM W8 The Savella® (Milnacipran) Pregnancy Registry: Interim Analysis and Enrollment Challenges
   

Hirsch DK1, Sinclair Roberts S2,3, Brown VD2, Palmer R1, McLean J2, Leclair D1. 1Forest Research Institute, Jersey City, NJ, United States, 2INC Research, LLC, Division of Post-Approval & Strategic Services, Wilmington, NC, United States, 3University of North Carolina Wilmington, Wilmington, NC, United States.

     
5:15 PM–5:30 PM W9 Trends in Post-Marketing Commitments for Pregnancy Registries in the Five Years since FDAAA
    Covington D, McKain L. Pharmaceutical Product Development, Inc., Wilmington, NC, United States.
     
5:30 PM–5:45 PM W10 Adverse Developmental Events Reported to US FDA in Association with Maternal Use of Topiramate in Pregnancy
    Tabacova S, Szarfman A. US Food and Drug Administration, Silver Spring, MD, United States.
     
5:45 PM–6:00 PM   Discussion

 

 

6:00 PM–8:00 PM

TS/NBTS/OTIS JOINT POSTER SESSION 1
(Including the National Children's Study Update)
AND EXHIBITS OPEN—Kiva Ballroom

Click Here to Browse Posters

P1

Primakova I, Doyle N, Martin AI, Pouliot L, Barbeau S, Samadfam R, Varela A, Smith SY, Robinson K. Charles River Laboratories, Preclinical Services, Montréal, Senneville Montreal, QC, Canada. Assessments of Skeletal Development in Rats and Rabbits Using Imaging Techniques

 

P2

Hilbish KG1, Breslin WJ1, Johnson JT1, Sloter ED2. 1Eli Lilly and Company, Indianapolis, IN, United States, 2WIL Research, Ashland, OH, United States. Fertility and Developmental Toxicity Assessment in Rats and Rabbits with LY500307, a Selective Estrogen Receptor Beta (ERb) Agonist Developed for the Treatment of Benign Prostatic Hyperplasia

 

P3

Hilbish KG1, Breslin WJ1, Johnson JT1, Sloter ED2. 1Eli Lilly and Company, Indianapolis, IN, United States, 2WIL Research, Ashland, OH, United States. Pre- and Postnatal Developmental Toxicity Assessment in Rats with LY500307: A Selective Estrogen Receptor Beta (ERb) Agonist Developed for the Treatment of Benign Prostatic Hyperplasia

 

P4

Lalayeva N1, Oneda S1, Makori N1, Watson R1, Jacobson S1, Glaza S1, Jackson K1, Sato K1, Beck T1, Fukuzaki K1, Nagata R2. 1SNBL USA, Ltd., Everett, WA, United States, 2Shin Nippon Biomedical Laboratories, Ltd., Tokyo, Japan. Infant Morphology Background Data from Pre- and Postnatal Developmental (ePPND) Studies in Cynomolgus Monkeys

 

P5

Watson R1, Oneda S1, Lalayeva N1, Makori N1, Glaza S1, Beck T1, Fukuzaki K1, Nagata R2. 1SNBL USA, Everett, WA, United States, 2SNBL Ltd., Tokyo, Japan. Hematology and Immunophenotyping Control Background Data in Mainland and Indonesian Origin Infant Monkeys

 

P6

Breslin WJ1, Hilbish KG1, Martin JA1, Halstead CA1, Newcomb DL2. 1Lilly Research Laboratories, Indianapolis, IN, United States, 2Charles River Laboratories, Reno, NV, United States. Pre- and Postnatal Development Toxicity Assessment in Cynomolgus Monkeys with Tabalumab, a Human IgG4 Monoclonal Antibody (mAb) for the Treatment of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)

 

P7

Breslin WJ1, Hilbish KG1, Martin JA1, Edwards TL2. 1Lilly Research Laboratories, Indianapolis, IN, United States, 2WIL Research, Inc., Ashland, OH, United States. Developmental Toxicity and Fertility Assessment in Rabbits with Tabalumab, a Human IgG4 Monoclonal Antibody under Development for Rheumatoid Arthritis and Systemic Lupus Erythematosus

 

P8

Fisher JE, Reid LL. Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States. Male-Mediated Developmental Toxicity: Recommendations on Male Contraceptive Use in Clinical Trials and Approved Drug Labeling

 

P9

Peterson SR1, Frey MT2,3, Gilboa SM2, Broussard CS2. 1Emory University, Atlanta, GA, United States, 2National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, GA, United States, 3Oak Ridge Institute for Science and Education, Oak Ridge, TN, United States. Public Perception of Risk Factors for Birth Defects: HealthStyles, 2010-2011

 

P10

HERNANDEZ MD1, ARREDONDO P2, GUTIERREZ JA2, MATA A3, GARZA J3, SILVA J4, VALERO E4, PEREZ E2, MADIN JA2, CHAVEZ MA5, MORALES H6, YAÑEZ JM7, ELIZONDO A8, DIAZ SJ9, OCHOA E2, GARZA BA10, MARTINEZ LE1, VILLARREAL JZ2. 1Hospital Universitario "Dr. José E. Gonzélez", Nuevo León, Mexico, 2Secretaría de Salud, Nuevo León, Mexico, 3Hospital Regional Materno Infantil, Nuevo León, Mexico, 4Hospital Metropolitano, Nuevo León, Mexico, 5Clínica Cuauhtemoc y Famosa, Nuevo León, Mexico, 6Clínica No. 23 IMSS, Nuevo León, Mexico, 7Hospital San José TEC de Monterrey, Nuevo León, Mexico, 8Clínica No. 33 IMSS, Nuevo León, Mexico, 9Hospital Sección 50, Nuevo León, Mexico, 10Asociación Espida Bífida, Nuevo León, Mexico. Incidence of Birth Defects in Nuevo Leon, Mexico: Preliminary Report of the Interinstitutional Surveillance Committee

 

P11

Ghassemi Jahani SA1, Danielson B2, Stromland K3, Karlsson J1, Danielsson A1. 1Sahlgrenska Academy, Dep of Orthopaedics, Gothenburg, Sweden, 2Sahlgrenska Academy, Dep of Radiology, Gothenburg, Sweden, 3Sahlgrenska Academy, Dep of Ophthalmology, Gothenburg, Sweden. Malformations and Development of Osteoarthritis in Patients with Thalidomide Embryopathy in Sweden

 

P12

Langlois PH1, Hoyt AT2, Lupo PJ3, Lawson CC4, Desrosiers TA5, Shaw GM6, Romitti PA7, Symanski E8, Reefhuis J9, Malik S10. 1Texas Department of State Health Services, Austin, TX, United States, 2Texas Department of State Health Services, Austin, TX, United States, 3Baylor College of Medicine, Houston, TX, United States, 4National Institute for Occupational Safety and Health, Cincinnati, OH, United States, 5University of North Carolina, Chapel Hill, NC, United States, 6Stanford University School of Medicine, Palo Alto, CA, United States, 7The University of Iowa, Iowa City, IA, United States, 8University of Texas School of Public Health, Houston, TX, United States, 9Centers for Disease Control and Prevention, Atlanta, GA, United States, 10University of Arkansas for Medical Sciences, Little Rock, AR, United States. Maternal Occupational Exposure to Polycyclic Aromatic Hydrocarbons and Risk of Selected Birth Defects

 

P13

Smith M1, Griffith WC1, Beresford S2,4, Vredevoogd M1,3, Vigoren EM1,3, Burbacher T3, Grant K3, Faustman EM1,3. 1Institute for Risk Analysis and Risk Communication, Seattle, WA, United States, 2Department of Epidemiology, Seattle, WA, United States, 3Northwest Center for the National Children’s Study, University of Washington, Seattle, WA, United States, 4Fred Hutchinson Cancer Research Center, Seattle, WA, United States. Development of a Sensitive and Rapid Quantitative Method to Measure Cortisol in Human Urine by Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry: Implications for the National Children's Study

 

P14

The National Children’s Study Placental Research Consortium 20, Miller RK1, Stodgell CJ1, Katzman PJ1, Friedman AE1, Jamerson D1, Friedman MR1, Salamone L1, Ruffolo LI1, Weidenborner P1, Aagaard-Tillery K2, Culhane J3, Wadlinger S3, Pacholski M3, Kent MA3, Green L3, Wapner R4, Torres C4, Perou J4, Landrigan P5, Chen J5, Lambertini L5, Littman L5, Sheffield P5, Golden A5, Gilbert J5, Lendor C5, Allen S5, Schadt E5, Dudley J5, Leuthner S6, Szabo S6, Salafia CM7, Dalton JL7, Misra D7, Thiex N8, Gutzman K8, Martin A8, Specker B8, Hobbs C9, MacCleod S9, Walker CK10, Swanson J11, Holliday C11, Butler J11, LI A12, Dassanayake RMAPS12, Nanes J12, Xia Y12, Murray JC13, Busch TD13, Rigdon J13, Darrah TH14,15, Campbell E14, Dole N16, Thorp J16, Eucker B16, Bell C16, Clark EB17, Varner MW17, Taggart E17, Billy J17, Stradling S17, Leavitt J17, Bell W17, Waterfall S17, O’Brien B18, Layton M18, Todd D18, Wilson K18, Durkin MS19, Sandoval M-N19, Kasten C20, Moye J20. 1University of Rochester, School of Medicine and Dentistry, Rochester, NY, United States, 2Baylor College of Medicine, Houston, TX, United States, 3The Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 4Columbia University, New York, NY, United States, 5Icahn School of Medicine at Mount Sinai, New York, NY, United States, 6Medical College of Wisconsin, Milwaukee, WI, United States, 7Placental Analytics, Inc., Larchmont, NY, United States, 8South Dakota State University, Brookings, SD, United States, 9University of Arkansas, Little Rock, AR, United States, 10University of California, Davis, Davis, CA, United States, 11University of California, Irvine, Irvine, CA, United States, 12University of Illinois, Chicago, Chicago, IL, United States, 13University of Iowa, Iowa City, IA, United States, 14University of Massachusetts, Boston, Boston, MA, United States, 15Duke University, Durham, NC, United States, 16University of North Carolina, Chapel Hill, Chapel Hill, NC, United States, 17University of Utah, Salt Lake City, UT, United States, 18Westat, Inc., Rockville, MD, United States, 19University of Wisconsin, Madison, WI, United States, 20National Children’s Study, NIH, Bethesda, MD, United States. Use of the Human Placenta As a Biomarker for Environmental Exposures and Clinical, Genetics/Epigenetic, Morphological, and Systems Biology Assessments in the National Children’s Study (NCS)

 

P15

Stodgell CJ1,2, Salamone L1,2, Katzman PK1,2, Ruffolo LI1,2, Murray J1,3, Busch T1,3, Culhane J1,4, Wadlinger S1,4, Landrigan P1,5, Littman L1,5, hiex N1,6, Specker B1,6, Swanson J1,7, Dole N1,8, Eucker B1,8, Clark EB1,9, Varner M1,9, Taggart E1,9, Moye J1,10, Miller RK1,2. 1National Children’s Study Placenta Consortium, Bethesda, MD, United States, 2University of Rochester, School of Medicine and Dentistry, Rochester, NY, United States, 3University of Iowa, School of Medicine, Iowa City, IA, United States, 4The Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 5Icahn School of Medicine at Mount Sinai, New York, NY, United States, 6South Dakota State University, Brookings, SD, United States, 7University of California, Irvine, Irvine, CA, United States, 8University of North Carolina, Chapel Hill, Chapel Hill, NC, United States, 9University of Utah, Salt Lake City, UT, United States, 10NIH, National Children’s Study, Bethesda, MD, United States. Gene Expression in Human Placenta from the National Children's Study (NCS)

 

P16

Darrah TH2,3, White AM1,2, Campbell ME1,2, Miller RK1,4, Stodgell CJ1,4, Katzman PJ1,4, Ruffolo L1,4, Weidenborner P1,4, Culhane J1,5, Wadlinger S1,5, Landrigan P1,6, Littman L1,6, Thiex N1,7, Specker B1,7, Swanson J1,8, Dole N1,9, Eucker B1,9, Clark EB1,10, Varner M1,10, Taggart E1,10, Moye J1,11. 1National Children's Study Placenta Consortium, Bethesda, MD, United States, 2Duke University, Nicholas School of the Environment, Durham, NC, United States, 3UUMass Boston, Environmental, Earth, and Ocean Sciences, Boston, MA, United States, 4University of Rochester, School of Medicine and Dentistry, Rochester, NY, United States, 5The Children's Hospital of Philadelphia, Philadelphia, PA, United States, 6Icahn School of Medicine at Mount Sinai, New York, NY, United States, 7South Dakota State University, Brookings, SD, United States, 8University of California, Irvine, Irvine, CA, United States, 9University of North Carolina, Chapel Hill, Chapel Hill, NC, United States, 10University of Utah, Salt Lake City, UT, United States, 11National Children's Study, NIH, Bethesda, MD, United States. Understanding the Trace Metal Composition of Human Placenta from the National Children's Study (NCS)

 

P17

Grant KS1, Stone W2, Ibanez L2, Vredevoogd M.1, Burbacher TM1, Faustman EM1, Newschaffer C3, Lampron Z3, Abdullah M4, Burkhom D5, Clarke N5, Durkin M6, Ferrell C7, Golden A8, Kuo A11, Lakes K4, Lambert B12, Landa R14, Landigran PJ7,8, Messinger D12,13, Paterson S15, Wang AT9,10, Warren Z16. 1Dept. of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, United States, 2Dept. of Psychology, University of Washington, Seattle, WA, United States, 3A.J. Drexel Autism Institute, Drexel University, Philadelphia, PA, United States, 4Dept. of Pediatrics, University of California, Irvine, Irvine, CA, United States, 5Center for Analytics and Public Health, Battelle Memorial Institute, Baltimore, MD, United States, 6Depts. of Population Health Sciences and Pediatrics, University of Wisconsin-Madison, Madison, WI, United States, 7Dept. of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 8Dept. of Preventive Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 9Dept. of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 10Dept. of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 11Depts of Pediatrics and Psychiatry, David Geffen School of Medicine, University of California. Los Angeles, Los Angeles, CA, United States, 12Dept. of Psychology, University of Miami,, Coral Gables, FL, United States, 13Dept. of Pediatrics, University of Miami, Coral Gables, FL, United States, 14Center for Autism and Related Disorders, Kennedy Krieger Institute, Baltimore, MD, United States, 15Center for Autism Research, Children’s Hospital of Philadelphia and Dept. of Pediatrics, University of Pennsylvania, Philadelphia, PA, United States, 16Depts. of Pediatrics and Psychatry, Vanderbilt University, Nashville, TN, United States. Advancing Early Diagnosis of Autism Spectrum Disorder for the National Children's Study

 

P18

The National Children’s Study Placental Research Team 1, Salafia CM1,2, Dalton JL1,2, Misra D1,2, Stodgell CJ1,3, Katzman PJ1,3, Ruffolo LI1,3, Culhane J1,4, Wadlinger S1,4, Torres C1,5, Landrigan P1,6, Littman L1,6, Sheffield P1,6, Leuthner S1,7, Szabo S1,7, Thiex N1,8, Specker B1,8, Swanson J1,9, Dole N1,10, Thorp J1,10, Eucker B1,10, Clark EB1,11, Varner MW1,11, Taggart E1,11, Durkin MS1,12, Sandoval M-N1,12, Moye J1,13, Miller RK1,3. 1National Children’s Study Placenta Consortium, Bethesda, MD, United States, 2Placental Analytics, Inc., Larchmont, NY, United States, 3University of Rochester, School of Medicine and Dentistry, Rochester, NY, United States, 4The Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 5Columbia University, New York, NY, United States, 6Icahn School of Medicine at Mount Sinai, New York, NY, United States, 7Medical College of Wisconsin, Milwaukee, WI, United States, 8South Dakota State University, Brookings, SD, United States, 9University of California, Irvine, Irvine, CA, United States, 10University of North Carolina, Chapel Hill, Chapel Hill, NC, United States, 11University of Utah, Salt Lake City, UT, United States, 12University of Wisconsin, Madison, WI, United States, 13NIH, National Children’s Study, Bethesda, MD, United States. The Chorionic Surface Vascular Network in Human Placenta: Quantifying Structure to Estimate Gestational Stressors and Life Course Risks, Autism Spectrum Disorder (ASD) As a Model for Future Analyses: National Children's Study and EARLI

   

8:00 PM–10:30 PM

TS/MARTA STUDENT CAREER EVENT—Upper Terrace

   


Share this page.